Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cue Biopharma (CUE) Cash from Financing Activities (2017 - 2025)

Cue Biopharma (CUE) has disclosed Cash from Financing Activities for 9 consecutive years, with $9.5 million as the latest value for Q4 2025.

  • Quarterly Cash from Financing Activities rose 1118.45% to $9.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $26.3 million through Dec 2025, up 156.67% year-over-year, with the annual reading at $26.3 million for FY2025, 156.67% up from the prior year.
  • Cash from Financing Activities hit $9.5 million in Q4 2025 for Cue Biopharma, up from $1000.0 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $27.4 million in Q4 2022 to a low of -$1.0 million in Q2 2024.
  • Historically, Cash from Financing Activities has averaged $6.1 million across 5 years, with a median of $3.5 million in 2023.
  • Biggest five-year swings in Cash from Financing Activities: surged 51088.89% in 2023 and later tumbled 147.6% in 2024.
  • Year by year, Cash from Financing Activities stood at $7.4 million in 2021, then soared by 271.2% to $27.4 million in 2022, then plummeted by 82.55% to $4.8 million in 2023, then crashed by 119.49% to -$932000.0 in 2024, then soared by 1118.45% to $9.5 million in 2025.
  • Business Quant data shows Cash from Financing Activities for CUE at $9.5 million in Q4 2025, $1000.0 in Q3 2025, and $17.8 million in Q2 2025.